Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 458

Sort by

Sort Order Select

Journal Articles

Hemopexin deficiency promotes acute kidney injury in sickle cell disease

Solomon F. Ofori-Acquah, Rimi Hazra, Oluwaseun O. Orikogbo, Danielle Crosby, Bethany Flage, Ezekiel B. Ackah, Diane Lenhart, Roderick J. Tan, Dario A. Vitturi, Vivian Paintsil, Ellis Owusu-Dabo, Samit Ghosh, in collaboration with the SickleGenAfrica Network

Blood (2020) 135 (13): 1044–1048.

https://doi.org/10.1182/blood.2019002653

Published: 2020

Includes: Supplemental data

Journal Articles

Relationship between Vaso-Occlusive Crises and Important Complications in Sickle Cell Disease Patients

Miranda Bailey, Ajibola Abioye, George Morgan, Tom Burke, MSc, Tim Disher, Stephen Brown, Ashley Bonner, Eleonore Herquelot, Ludovic Lamarsalle, Fanny Raguideau

Blood (2019) 134 (Supplement_1): 2167.

https://doi.org/10.1182/blood-2019-131721

Published: 2019

Journal Articles

Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia

Kylee L Martens, MD, Parisa R Khalighi, BS, Shan Li, PharmD, Andrew A White, MD, Emily Silgard, MS, Deborah Frieze, PharmD, Elihu H. Estey, MD, David A. Garcia, MD, Sangeeta R Hingorani, MD MPH, Ang Li, MD

Blood (2019) 134 (Supplement_1): 4674.

https://doi.org/10.1182/blood-2019-124058

Published: 2019

Journal Articles

Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome in Pregnancy: A Single Center Retrospective Review

Pallavi Kopparthy, MD, Anita Rajasekhar, MD

Blood (2019) 134 (Supplement_1): 4899.

https://doi.org/10.1182/blood-2019-131846

Published: 2019

Journal Articles

Outcomes Related to Intravenous Fluid Administration in Sickle Cell Patients during Vaso-Occlusive Crisis

Daria Gaut, MD, Jennifer Jones, MD, Caroline Chen, MD, Sanaz Ghafouri, MD, Mei Ling, MD, Roswell Quinn, MD PhD

Blood (2019) 134 (Supplement_1): 992.

https://doi.org/10.1182/blood-2019-121945

Published: 2019

Journal Articles

Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex

Hui-qiang Huang, Gao Yan, Hang Su, Yunhong Huang, Yuhuan Gao, Wang Xiaoxiao, Bai Bing, Yujing Zhang, Liping Su, Xiaoxia Chu, Wenyu Li, MD PhD, Junyi Zhang, Qiaohua Zhang, MD, Liansheng Zhang, Xiaohua Hu, Liqun Zou, Zhiming Li, Wenqi Jiang

Blood (2019) 134 (Supplement_1): 1569.

https://doi.org/10.1182/blood-2019-123478

Published: 2019

Journal Articles

Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury

William E Plautz, BS, Mitchell Dyer, MD MSc, Margaret V. Ragni, MD MPH, Shannon Haldeman, Wyeth E Alexander, BS, Jason Sperry, Francis Guyette, Brian Zuckerbraun, Marian A. Rollins-Raval, MD MHP, Jay S Raval, MD, Matthew D Neal, MD

Blood (2019) 134 (Supplement_1): 444.

https://doi.org/10.1182/blood-2019-124531

Published: 2019

Journal Articles

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Kenneth I. Ataga, MD, Santosh L. Saraf, MD, Vimal K. Derebail, MD, Claire C. Sharpe, Adlette Inati, MD, Jeffrey D. Lebensburger, DO, MSPH, Laurie DeBonnett, MD, Shirong Zhang, Pablo Bartolucci, MD PhD

Blood (2019) 134 (Supplement_1): 1018.

https://doi.org/10.1182/blood-2019-124823

Published: 2019

Journal Articles

Congenital FVIII/IX or VWF Deficiency Does Confer a Lower Rate of Myocardial Infarction-Related Mortality Despite Decreased Cardiovascular Interventions

Fateeha Furqan, MD, Nicolas Goldstein, Peter A. Kouides, MD

Blood (2019) 134 (Supplement_1): 1120.

https://doi.org/10.1182/blood-2019-131387

Published: 2019

Journal Articles

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Blood (2019) 134 (Supplement_1): 2647.

https://doi.org/10.1182/blood-2019-122477

Published: 2019

Journal Articles

Outcomes of Patients with Chronic Lymphocytic Leukemia Admitted with Sepsis: An Analysis of National Inpatient Sample Database

Prasanth Lingamaneni, Muhammad Zain Farooq, MD MBBS, Ishaan Vohra, MD, Shristi Upadhyay, MD, Sindhu Malapati, MD, Sunny R K Singh, MD

Blood (2019) 134 (Supplement_1): 5460.

https://doi.org/10.1182/blood-2019-131646

Published: 2019

Journal Articles

Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study

Agoston Gyula Szabo, MD, Jonathan Thorsen, MD PhD, Charlotte Toftmann Hansen, MD PhD, Maja Ølholm Vase, MD PhD, Manuela Teodorescu, MD, Simon Bo Pedersen, MD, Simon Bertram Flæng, MD, Ulf Christian Frølund, MD, Annette Juul Vangsted, MD PhD, Torben Plesner, MD DSc

Blood (2019) 134 (Supplement_1): 5553.

https://doi.org/10.1182/blood-2019-124336

Published: 2019

Journal Articles

Comparison of Fixed Dose, Reduced-Intensity Conditioning with Busulfan and Fludarabine to Reduced PK-Guided Busulfan AUC Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplant for AML/MDS

Brendan Rasor, PharmD, Tyler Dickerson, PharmD, Qiuhong Zhao, MS, Jonathan E Brammer, MD, Karilyn Larkin, MD, Samantha Jaglowski, MDMPH, Alice S. Mims, MD, Sam Penza, MD, Sumithira Vasu, MDMBBS, Sarah A Wall, MD, Basem M. William, MRCP,MD, Ayman Saad, MD, Julianna Roddy, PharmD, Hannah K. Choe, MD, Marcin Puto, PharmD

Blood (2019) 134 (Supplement_1): 5715.

https://doi.org/10.1182/blood-2019-123657

Published: 2019

Journal Articles

Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant

Sayeef Mirza, MDMPH, Ankita Tandon, DO, Dakota Jenneman, MD, Shu Cao, MD, Ambuj Kumar, MD MPH, Michelle R. Kidd, PharmD, Farhad Khimani, MD, Asmita Mishra, MD, Hien D. Liu, MD, Taiga Nishihori, MD, Lia Perez, MD, Nelli Bejanyan, MD, Joseph Pidala, MD, Michael Nieder, MD, Hany Elmariah, MD MS

Blood (2019) 134 (Supplement_1): 5673.

https://doi.org/10.1182/blood-2019-127370

Published: 2019

Journal Articles

Early Salvage Treatment with Second-Generation Novel Agents at Biochemical Relapse Prolongs Overall Survival: A Real-World Single Center Experience

Uros Markovic, MD, Valerio Leotta, MD, Alessandra Romano, MD PhD, Vittorio Del Fabro, MD, Giuseppe Sapienza, MD, Enrica Antonia Martino, MD, Marina Parisi, MD, Valeria Calafiore, Francesco Di Raimondo, MD, Concetta Conticello, MD

Blood (2019) 134 (Supplement_1): 5530.

https://doi.org/10.1182/blood-2019-130415

Published: 2019

Journal Articles

Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients

Jingjing Shang, Weiqin Yao, Lingzhi Yan, Xiaolan Shi, Ruju Wang, Shuang Yan, Yong Liu, Depei Wu, MD PhD, Fu Cheng Cheng, MD PhD

Blood (2019) 134 (Supplement_1): 1855.

https://doi.org/10.1182/blood-2019-129434

Published: 2019

Journal Articles

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Mamta Garg, MD FRCP, FRCPath, Andrew Hall, Matthew Jenner, MBBS, MRCP, FRCPath, Bhuvan Kishore, MB BS, MRCP, FRCPath, Helen J Lachmann, MA MB BChir MDFRCP, Julian D Gillmore, MBBS, MD PhD FRCP, Alexandra Pitchford, Louise Flanagan, PhD, Jamie B Oughton, MPhil, BSc, Shameem Mahmood, Sajitha Sachchithanantham, Sarah R Brown, PhD MSc, BSc, Ashutosh D Wechalekar, MBBS, MD FRCP, FRCPath, DM

Blood (2019) 134 (Supplement_1): 1890.

https://doi.org/10.1182/blood-2019-126567

Published: 2019

Journal Articles

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Ola Landgren, MD PhD, Michel Attal, MD PhD, Dickran Kazandjian, MD, Murielle Roussel, MD, Jagoda K. Jasielec, MD, Dominik Dytfeld, Aparna Anderson, Tara Kervin, Karim Iskander, Khalid Mezzi, Tim Welliver, Akeem Yusuf, PhD BPharm, Andrzej Jakubowiak, MD PhD

Blood (2019) 134 (Supplement_1): 1891.

https://doi.org/10.1182/blood-2019-127076

Published: 2019

Journal Articles

Impact of Preemptive Leucovorin Dose Escalation on Incidence of Delayed Methotrexate Elimination in Lymphoma Patients Receiving High-Dose Methotrexate

Jason N Barreto, PharmD, Erin F Barreto, PharmD, Kristen T Peterson, PharmD, Ross Dierkhising, MS, Kristin C. Mara, MS., Nelson Leung, MD, Carrie A. Thompson, MD

Blood (2019) 134 (Supplement_1): 1621.

https://doi.org/10.1182/blood-2019-123281

Published: 2019

Journal Articles

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Eftathios Kastritis, Nikolaos Kanellias, MD, Foteini Theodorakakou, MD, Erasmia Psimenou, MD, Charikleia Gakiopoulou, MD, Smaragdi Marinaki, Maria Roussou, MD, Maria Gavriatopoulou, MD, Magdalini Migkou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Panagiotis Malandrakis, MD, Evangelos Terpos, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1776.

https://doi.org/10.1182/blood-2019-126385

Published: 2019

NARROW

Hemopexin deficiency promotes acute kidney injury in sickle cell disease

Relationship between Vaso-Occlusive Crises and Important Complications in Sickle Cell Disease Patients

Comparative Effectiveness of Rasburicase Versus Allopurinol for Cancer Patients with Renal Dysfunction and Hyperuricemia

Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome in Pregnancy: A Single Center Retrospective Review

Outcomes Related to Intravenous Fluid Administration in Sickle Cell Patients during Vaso-Occlusive Crisis

Clinical Outcome of an Multicentre, Randomized, Phase II Clinical Trial for Patients with Extranodal NK/T Cell Lymphoma Treated By P-Gemox or Aspametdex

Prolonged Circulation of Ultra-Large Von Willebrand Factor and a Reduction in ADAMTS13 Activity Promotes Microvascular Disease Following Traumatic Injury

The Effect of Crizanlizumab Plus Standard of Care (SoC) Versus Soc Alone on Renal Function in Patients with Sickle Cell Disease and Chronic Kidney Disease: A Randomized, Multicenter, Open-Label, Phase II Study (STEADFAST)

Congenital FVIII/IX or VWF Deficiency Does Confer a Lower Rate of Myocardial Infarction-Related Mortality Despite Decreased Cardiovascular Interventions

Venetoclax Combined with Cladribine + Low Dose AraC (LDAC) Alternating with 5-Azacytidine Produces High Rates of Minimal Residual Disease (MRD) Negative Complete Remissions (CR) in Older Patients with Newly Diagnosed Acute Myeloid Leukemia (AML)

Outcomes of Patients with Chronic Lymphocytic Leukemia Admitted with Sepsis: An Analysis of National Inpatient Sample Database

Clinically Suspected Cast Nephropathy: A Retrospective, Multi-Center, Real-World Study

Comparison of Fixed Dose, Reduced-Intensity Conditioning with Busulfan and Fludarabine to Reduced PK-Guided Busulfan AUC Conditioning in Patients Undergoing Hematopoietic Stem Cell Transplant for AML/MDS

Outcomes Following Intolerance to Tacrolimus/Sirolimus for Graft-Versus-Host Disease Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant

Early Salvage Treatment with Second-Generation Novel Agents at Biochemical Relapse Prolongs Overall Survival: A Real-World Single Center Experience

Initial Safety and Efficacy of Dose-Escalating HDACs Inhibitor Chidamide with VRD (Chi-VRD) Treatment for Newly-Diagnosed High-Risk Transplant Eligible Multiple Myeloma Patients

A Phase 1 Study of Carfilzomib-Thalidomide-Dexamethasone in Patients with Relapsed/Refractory AL Amyloidosis - Catalyst Trial Results

Efficacy and Safety of Carfilzomib-Lenalidomide-Dexamethasone (KRd) in Newly Diagnosed Multiple Myeloma: Pooled Analysis of 4 Single-Arm Studies

Impact of Preemptive Leucovorin Dose Escalation on Incidence of Delayed Methotrexate Elimination in Lymphoma Patients Receiving High-Dose Methotrexate

Renal Pathology in Patients with Monoclonal Gammopathy or Multiple Myeloma: Monoclonal Immunoglobulins Are Not Always the Cause

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only